Key result
Sacubitril/valsartan consistently outperforms valsartan regardless of in-hospital or outpatient initiation in HF with LVEF >40%.
Why the study?
The efficacy and tolerability of in-hospital initiation of sacubitril/valsartan were not well characterized in patients with heart failure and ejection fraction >40%.
RCT
Answers are grounded in this paper and cite their sources.
Supports in-hospital Sac/Val initiation in decompensated HFpEF; extends outpatient RCT evidence to acute worsening HF.
BACKGROUND: Efficacy and tolerability of sacubitril/valsartan (Sac/Val) is not well characterized in heart failure (HF) with ejection fraction >40% initiated in-hospital. Thus, this prespecified PARAGLIDE-HF (Prospective Comparison of ARNI With ARB Given Following Stabilization In Decompensated HFpEF) analysis assessed the effects of Sac/Val versus valsartan (Val) by location of initiation in HF with ejection fraction >40% and recent worsening HF. METHODS AND CONCLUSIONS: Sac/Val provided consistent benefit compared with Val, whether initiated in-hospital or out-of-hospital in HF with ejection fraction >40% with a recent worsening HF event, demonstrating an opportunity to improve postdischarge outcomes by initiating Sac/Val during hospitalization.
No takes yet. Share an insight, caveat, or question.
Nouhravesh et al. (2025) conducted an RCT in Heart failure with ejection fraction >40% and recent worsening HF. Sacubitril/Valsartan vs. Valsartan was evaluated. Sacubitril/valsartan provided consistent benefit compared with valsartan, whether initiated in-hospital or out-of-hospital in heart failure with ejection fraction >40%.
Synapse has enriched 10 related papers. Consider them for comparative context: